Compare Equitable Holdings Inc. Common Stock (EQH) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs GSK plc — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B), while GSK plc trades at $47.87 (market cap $92.78B). The key difference: GSK plc is far larger — about 6.4× Equitable Holdings Inc. Common Stock's market cap, and GSK plc pays the higher dividend (3.92%). Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and GSK plc for 93 Days on average.
| EQH | GSK | |
|---|---|---|
Market Cap | $14.49B | $92.78B |
Volume | 2,405,401 | 5,756,402 |
Sector | Financials | Health |
52-Week High | $54.50 | $61.18 |
52-Week Low | $35.34 | $43.24 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $5.54B | $112.77B |
Dividend Yield | 2.15% | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
